Health
Study finds proteins can predict who will get dementia in 10 years
A study of frozen blood samples has revealed a trove of proteins that can predict some forms of dementia more than 10 years before the
US FDA officials raise no new concerns about Abbott’s heart device
Experts at the US Food and Drug Administration have raised no new concerns about the safety and effectiveness of Abbott’s heart valve repair device for
Bayer CEO says the company supports glyphosate
Bayer’s CEO said on Friday that the health and crop chemicals group continues to stand firmly behind its glyphosate-based weedkiller even after recently losing a
Shares of Moderna and Metagenomi, backed by Bayer, fell 32%
Shares of Metagenomi Technologies, a genetic drug company backed by Bayer Healthcare, opens a new tab and Moderna, opens a new tab, fell 32% during
Walgreens Boots received $992m after cutting its stake in Cencora for the third time
US pharmacy chain Walgreens Boots Alliance said it had reduced its stake in pharmaceutical distributor Cencora, for the third time in just over six months,
Dengue is spreading rapidly in Brazil
Dengue fever has spiked in Brazil during the hot rainy season, prompting health authorities to take emergency measures and start mass vaccination against the mosquito-borne
High doses of opioid reversal spray are no better than lower doses in the field
A high-dose version of the opioid-reversal spray naloxone, manufactured by Hikma Pharmaceuticals, did not result in increased survival compared with lower-dose versions of the drug
AstraZeneca to invest $300m in US cell therapy centre
AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland, to discover and develop cell therapies. The U.S. facility will
U.S. FDA finds control violations at Catalent plant
In November, US drug regulators found quality control violations at contract drug maker Catalent’s plant in Bloomington, Indiana, including the discovery of “pests” on the
Gilead’s quarterly revenue falls 4%, COVID oral drug fails to pass trials
Gilead Sciences said fourth-quarter revenue fell 4 per cent due to lower sales of its HIV drugs and Veklury, a drug contained in them to